Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/
The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed.
“This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Microbiome, Ferring Pharmaceuticals. “This collaboration is a successful example of our strategy to use external innovation to build our pipeline complementary to our in-house research; and we aim to do further collaborations to build a vibrant research community.”
Tomas de Wouters, CEO, PharmaBiome said: “The trust of Ferring in our translational approach is an important validation of our work and a unique opportunity to accelerate the development of our rationally designed consortia with an experienced market leader in the microbiome therapeutic field. We are thrilled about the complementary expertise between our companies and look forward to a fruitful collaboration. ”
Based on two core technologies, PharmaBiome has developed a unique technology platform to select bacterial strains for the design of bacterial consortia as live biotherapeutic products with defined activities - the NicheMap™ and a co-cultivation approach that enables fast and scalable production. PharmaBiome’s programmes aim at a next generation of products that are independent of donor material and deliver exactly the consortium of bacterial strains with the desired activity and therapeutic effect (“defined consortia”).
Ferring is the first company to successfully bring forward a first-in-class FDA approved live microbiome-based therapy to US patients. In addition, Ferring has the proven scale and ability to drive forward clinical trials and manufacture microbiome-based products in what is a pioneering field and has a long heritage within gastroenterology.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).
About PharmaBiome
PharmaBiome is a biotech company developing therapeutic consortia using gut bacteria for targeted modification of microbiome composition and activity. PharmaBiome’s drug-development platform includes an in vitro culture based technology enabling the quantitative understanding of the link between microbiome composition and activity, the NicheMap™.
Discover more about PharmaBiome: www.pharmabiome.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231210383233/en/
Contact information
Matthew Worrall
Director, Corporate Communications and Public Affairs, Ferring
+447442 271811
Matthew.Worrall@ferring.com
Tomas de Wouters
CEO, PharmaBiome
+41 44 552 03 04
media@pharmabiome.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Electricity and Water Authority PJSC Reports a Record AED 14.6 Billion in Revenue for the First Half of 2025 and Approves Dividend Payment of AED 3.1 Billion8.8.2025 18:47:00 EEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first half 2025 consolidated financial results, recording first half revenue of AED 14.6 billion, EBITDA of AED 7.0 billion, operating profit of AED 3.7 billion, net profit of AED 2.9 billion and cash from operations of AED 9.2 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808832927/en/ Dubai Electricity and Water Authority PJSC reports a record AED 14.6 billion in revenue for the first half of 2025 and approves dividend payment of AED 3.1 billion (Graphic: AETOSWire) “DEWA is committed to be an innovative and sustainable corporation inspired by the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highn
Philippine Government and Sutherland Launch AI Academy to Equip Filipinos with Future-Ready Skills8.8.2025 16:54:00 EEST | Press release
Sutherland, a global leader in business and digital transformation, has partnered with the Philippine Government to launch a dedicated AI Academy. This strategic initiative supports the Philippine government’s broader efforts to empower the Filipino workforce for an AI-driven future. The AI Academy will offer practical, industry-aligned training designed to equip Filipino professionals with skills to integrate artificial intelligence into their work. It aims to strengthen the country’s talent pool by developing capabilities that are increasingly in demand across sectors, whether as AI specialists, prompt engineers, or cybersecurity professionals. The program will prepare participants to harness AI in driving productivity, advancing innovation, and pursuing high-value opportunities across industries. “This initiative is a vital step toward our goal of building a digitally resilient and inclusive workforce, said President Ferdinand R. Marcos Jr. “By expanding access to training in future
Baraja Appoints IP Pioneer to Lead Global Sale of Spectrum-Scan™ LiDAR IP Assets8.8.2025 16:00:00 EEST | Press release
Baraja Pty Ltd (“Baraja”), the Australian pioneer behind the revolutionary Spectrum‑Scan™ LiDAR architecture, has announced a global initiative to commercialize its full suite of patented LiDAR intellectual property and technical assets. The company has appointed IP Pioneer Group Incas the exclusive worldwide advisor to manage this competitive transaction process. Baraja redefined LiDAR performance through its Spectrum-Scan™ technology—a transformative solid-state architecture that steers the laser beam by tuning its wavelength through a dispersive prism or grating, eliminating moving parts. This breakthrough enables long-range, high-resolution 3D sensing that is inherently immune to alignment drift, sunlight, and multi-LiDAR interference. Having achieved significant technical milestones in LiDAR innovation, Baraja is now strategically evolving its business focus to pursue new frontiers in sensing and perception. This initiative will allow a new commercial partner to capitalize on the
Graanul - Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation8.8.2025 13:54:00 EEST | Press release
Graanul: Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation for Graanul’s: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and, together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and tog
Traka Celebrates 30 Years of Innovation in Intelligent Key and Asset Management8.8.2025 12:00:00 EEST | Press release
Traka, an ASSA ABLOY company and global leader in intelligent key and equipment management solutions, is excited to announce its 30 years of innovation in intelligent key and asset management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808492250/en/ Traka is celebrating its 30th anniversary this year after its inception in 1995. What began as a custom solution for British Airways has grown into a global leader in intelligent key and asset management. Traka, now celebrating its 30th anniversary, is marking three decades of innovation, expansion, and impact across more than 30 industries worldwide. In 1995, Traka’s founder, John Kent, responded to a unique challenge: British Airways needed a secure and trackable way to manage critical keys, something the market didn’t yet offer. Kent built the first Traka key cabinet, setting the foundation for what would become a new category in access management. That first electronic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom